{"transactions":[{"id":711128,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-07-10T16:15:08.000Z","date":"2026-07-08","kind":"grant","planned":false,"acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and becomes exercisable on the earlier to occur of (i) July 8, 2027 or (ii) the day immediately prior to the first annual meeting of the Company's stockholders occurring after July 8, 2026."}],"balance_after":6500,"derivative":{"exercise_price":7.14,"expiration_date":"2036-07-07","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001193125-26-300920","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000119312526300920/ownership.xml","form_type":"4"}},{"id":741473,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T18:23:03.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":1.23,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0001193125-26-267255","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000119312526267255/ownership.xml","form_type":"4"}},{"id":750010,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-04T22:04:30.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":7490,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 2, 2026. Price not applicable."}],"balance_after":46440,"source":{"system":"sec-edgar","filing":"0001628280-26-040911","document":"wk-form4_1780610668.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000162828026040911/wk-form4_1780610668.xml","form_type":"4"}},{"id":946477,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":56.5,"underlying":"Common Stock","underlying_shares":2200},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946476,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":734,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":216,"underlying":"Common Stock","underlying_shares":734},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946475,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":90.5,"underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946474,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":513,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":161,"underlying":"Common Stock","underlying_shares":513},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946473,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1002,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":372.5,"underlying":"Common Stock","underlying_shares":1002},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946472,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":125,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":527.25,"underlying":"Common Stock","underlying_shares":125},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946471,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":368,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":572.5,"underlying":"Common Stock","underlying_shares":368},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946470,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":134,"underlying":"Common Stock","underlying_shares":450},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946469,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":107.75,"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946468,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":544,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":107.75,"underlying":"Common Stock","underlying_shares":544},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946467,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the \"Acceleration Date\"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an \"OTM Option\"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the \"Last Exercise Date\"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option."}],"balance_after":0,"derivative":{"exercise_price":434.5,"underlying":"Common Stock","underlying_shares":800},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946466,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2460,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock (\"Issuer Option\") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a \"Cash-Out Option\"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option."}],"balance_after":0,"derivative":{"exercise_price":9.0775,"underlying":"Common Stock","underlying_shares":2460},"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":946465,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-06T21:52:54.000Z","date":"2026-01-06","kind":"other","planned":false,"acquired":false,"shares":1567,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"kind","element":"transactionCoding","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Day One Biopharmaceuticals, Inc. (\"Parent\") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. (\"Purchaser\"), dated as of November 12, 2025, the shares (the \"Shares\") of common stock, par value $0.0001 per share, of the Issuer (the \"Common Stock\") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the \"Upfront Cash Consideration\"), plus (ii) one non-tradeable contingent value right per Share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the \"Offer Price\"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the \"Effective Time\"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-26-001382","document":"tm261736-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465926001382/tm261736-10_4seq1.xml","form_type":"4"}},{"id":1111481,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T21:02:42.000Z","date":"2025-06-12","kind":"grant","planned":false,"acquired":true,"shares":61500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2026 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":61500,"derivative":{"exercise_price":0.36,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":61500},"source":{"system":"sec-edgar","filing":"0001104659-25-059443","document":"tm2517941-7_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465925059443/tm2517941-7_4seq1.xml","form_type":"4"}},{"id":1113160,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:36:15.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":21000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest and become exercisable upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) the date of the Company's 2026 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on such vesting date."}],"balance_after":21000,"derivative":{"exercise_price":1.57,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":21000},"source":{"system":"sec-edgar","filing":"0000950170-25-085488","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000095017025085488/ownership.xml","form_type":"4"}},{"id":1137822,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-22T20:54:23.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":6650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 20, 2025. Price not applicable."}],"balance_after":38950,"source":{"system":"sec-edgar","filing":"0001048477-25-000068","document":"wk-form4_1747947254.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000068/wk-form4_1747947254.xml","form_type":"4"}},{"id":1173241,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-04-11T20:05:04.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of April 10, 2026 or the day immediately prior to the company's 2026 annual meeting of shareholders."}],"balance_after":100000,"derivative":{"exercise_price":0.58,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-25-053243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000095017025053243/ownership.xml","form_type":"4"}},{"id":1481970,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-12T20:51:05.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.26,"expiration_date":"2034-06-10","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001104659-24-070894","document":"tm2417031-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924070894/tm2417031-2_4seq1.xml","form_type":"4"}},{"id":1504165,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-23T21:20:28.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":4720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 21, 2024. Price not applicable."}],"balance_after":32300,"source":{"system":"sec-edgar","filing":"0001048477-24-000098","document":"wk-form4_1716499215.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000104847724000098/wk-form4_1716499215.xml","form_type":"4"}},{"id":1545378,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-04-08T20:45:12.000Z","date":"2024-04-04","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of April 4, 2025 or the day immediately prior to the company's 2025 annual meeting of shareholders."}],"balance_after":60000,"derivative":{"exercise_price":0.76,"expiration_date":"2034-04-03","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-042652","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000095017024042652/ownership.xml","form_type":"4"}},{"id":1549166,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-04-04T00:11:52.000Z","date":"2024-04-01","kind":"grant","planned":false,"acquired":true,"shares":78636,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.33% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 24 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date."}],"balance_after":78636,"derivative":{"exercise_price":10.82,"expiration_date":"2034-03-31","underlying":"Common Stock","underlying_shares":78636},"source":{"system":"sec-edgar","filing":"0000950170-24-041471","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000095017024041471/ownership.xml","form_type":"4"}},{"id":1687623,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-01-04T21:11:57.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":6112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash.  The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy, as amended, in lieu of retainer fees of $13,875 for the quarter ended December 31, 2023.  The number of shares issued was based on the closing price per share of the Issuer's common stock on January 2, 2024, which was $2.27."}],"balance_after":39182,"source":{"system":"sec-edgar","filing":"0001104659-24-001360","document":"tm241899-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465924001360/tm241899-2_4seq1.xml","form_type":"4"}},{"id":1765223,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-04T20:30:51.000Z","date":"2023-10-02","kind":"grant","planned":false,"acquired":true,"shares":11011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash. The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $13,875 for the quarter ended September 30, 2023. The number of shares issued was based on the closing price per share of the Issuer's common stock on October 2, 2023, which was $1.26."}],"balance_after":33070,"source":{"system":"sec-edgar","filing":"0001104659-23-106841","document":"tm2327613d4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923106841/tm2327613d4_4seq1.xml","form_type":"4"}},{"id":1833757,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-07-06T20:19:41.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":4217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash.  The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $13,875 for the quarter ended June 30, 2023.  The number of shares issued was based on the closing price per share of the Issuer's common stock on June 30, 2023, which was $3.29."}],"balance_after":22059,"source":{"system":"sec-edgar","filing":"0001104659-23-078750","document":"tm2320657-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923078750/tm2320657-2_4seq1.xml","form_type":"4"}},{"id":1845065,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-23T21:21:22.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 22, 2024 or the day immediately prior to the company's 2024 annual meeting of shareholders."}],"balance_after":35000,"derivative":{"exercise_price":5.46,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-23-016395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924323016395/doc4.xml","form_type":"4"}},{"id":1858667,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-12T20:13:39.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":18355,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":18355,"derivative":{"exercise_price":8.64,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":18355},"source":{"system":"sec-edgar","filing":"0001104659-23-070350","document":"tm2318463-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070350/tm2318463-1_4seq1.xml","form_type":"4"}},{"id":1858666,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-12T20:13:39.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":14467,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted stock unit (\"RSU\") award. Each RSU represents the contingent right to receive one share of Common Stock of the Issuer."},{"field":"shares","element":"transactionShares","label":"F2","text":"The award will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continuous service with the Issuer on such vesting date."}],"balance_after":17842,"source":{"system":"sec-edgar","filing":"0001104659-23-070350","document":"tm2318463-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923070350/tm2318463-1_4seq1.xml","form_type":"4"}},{"id":1880113,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-24T22:24:53.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":4190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 23, 2023. Price not applicable."}],"balance_after":27580,"source":{"system":"sec-edgar","filing":"0001209191-23-031967","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000120919123031967/doc4.xml","form_type":"4"}},{"id":1924924,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-05T21:12:15.000Z","date":"2023-04-03","kind":"grant","planned":false,"acquired":true,"shares":3375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares were granted in connection with the Reporting Person's election to receive the Reporting Person's quarterly retainer for director services in the form of fully vested shares of stock rather than cash. The shares were granted to the Reporting Person pursuant to the Issuer's Amended & Restated Non-Employee Director Compensation Policy in lieu of retainer fees of $13,875 for the quarter ended March 31, 2023. The number of shares issued was based on the closing price per share of the Issuer's common stock on March 31, 2023, which was $4.11."}],"balance_after":3375,"source":{"system":"sec-edgar","filing":"0001104659-23-042238","document":"tm2311858-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465923042238/tm2311858-1_4seq1.xml","form_type":"4"}},{"id":2185535,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-08-15T16:16:39.000Z","date":"2022-08-15","kind":"disposition_to_issuer","acquired":false,"shares":10000,"price":3.6,"value":36000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, these options automatically vested and were cancelled, by virtue of the Merger and without any action on the part of the Reporting Person, and the Reporting Person was entitled to receive (without interest) (A) an amount in cash (less applicable Tax withholdings) equal to the product of (x) the total number of Shares subject to such option immediately prior to the effective time multiplied by (y) the excess, if any, of the Cash Consideration over the applicable exercise price per Share under such option, and (B) one CVR for each Share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":6.4,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-22-028641","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000089924322028641/doc4.xml","form_type":"4"}},{"id":2185534,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T16:16:39.000Z","date":"2022-08-15","kind":"disposition_to_issuer","acquired":false,"shares":1895,"price":10,"value":18950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-028641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000089924322028641/doc4.xml","form_type":"4"}},{"id":2185533,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-15T16:16:39.000Z","date":"2022-08-15","kind":"other","acquired":false,"shares":21300,"price":10,"value":213000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of the Merger Agreement and the Tender Offer Statement on Schedule TO filed by Ginger Merger Sub, Inc., these Shares were tendered and disposed of at the Acceptance Time in exchange for the right to receive the consideration per Share of (i) $10.00, payable to the holder thereof of cash, without interest but subject to reduction for any applicable withholding Taxes payable in respect thereof, and (ii) one CVR per share."}],"balance_after":1895,"source":{"system":"sec-edgar","filing":"0000899243-22-028641","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000089924322028641/doc4.xml","form_type":"4"}},{"id":2211669,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"COMMON STOCK","published_at":"2022-07-06T23:22:42.000Z","date":"2022-07-05","kind":"grant","acquired":true,"shares":31746,"price":3.15,"value":99999.9,"ownership":{"direct":true},"balance_after":31746,"source":{"system":"sec-edgar","filing":"0000899243-22-025513","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924322025513/doc4.xml","form_type":"4"}},{"id":2221909,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-24T20:30:14.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 22, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders."}],"balance_after":35000,"derivative":{"exercise_price":3.22,"expiration_date":"2032-06-21","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000899243-22-023972","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924322023972/doc4.xml","form_type":"4"}},{"id":2235788,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-10T20:20:38.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of the first anniversary of the date of grant or the date of the 2023 Annual Meeting of Stockholders of Mersana Therapeutics, Inc., subject to the Reporting Person's continued service on such vesting date."}],"balance_after":45000,"derivative":{"exercise_price":3.62,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001104659-22-070143","document":"tm2218135-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922070143/tm2218135-5_4seq1.xml","form_type":"4"}},{"id":2255591,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-27T00:29:32.000Z","date":"2022-05-24","kind":"grant","acquired":true,"shares":4980,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 24, 2022.  Price not applicable."}],"balance_after":23390,"source":{"system":"sec-edgar","filing":"0001567619-22-011788","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761922011788/doc1.xml","form_type":"4"}},{"id":2426585,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-25T16:30:12.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":6.4,"expiration_date":"2032-01-14","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-004782","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919122004782/doc4.xml","form_type":"4"}},{"id":2426584,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-01-25T16:30:12.000Z","date":"2022-01-14","kind":"grant","acquired":true,"shares":5500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock  units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date."}],"balance_after":23195,"source":{"system":"sec-edgar","filing":"0001209191-22-004782","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919122004782/doc4.xml","form_type":"4"}},{"id":2443719,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T22:01:52.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":12847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2022."}],"balance_after":12847,"derivative":{"exercise_price":6.44,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":12847},"source":{"system":"sec-edgar","filing":"0001104659-22-001552","document":"tm221771-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465922001552/tm221771-1_4seq1.xml","form_type":"4"}},{"id":2660686,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-21T20:30:44.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":23000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 16, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders."}],"balance_after":23000,"derivative":{"exercise_price":19.74,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":23000},"source":{"system":"sec-edgar","filing":"0000899243-21-024993","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924321024993/doc4.xml","form_type":"4"}},{"id":2668160,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-15T22:03:20.000Z","date":"2021-06-11","kind":"grant","acquired":true,"shares":25050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2022 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":25050,"derivative":{"exercise_price":14.9,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":25050},"source":{"system":"sec-edgar","filing":"0001104659-21-081609","document":"tm2119714-4_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921081609/tm2119714-4_4seq1.xml","form_type":"4"}},{"id":2693918,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-05-27T21:20:02.000Z","date":"2021-05-25","kind":"grant","acquired":true,"shares":5120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 25, 2021.  Price not applicable."}],"balance_after":18410,"source":{"system":"sec-edgar","filing":"0001567619-21-011288","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761921011288/doc1.xml","form_type":"4"}},{"id":2839108,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-23T17:53:16.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in full on the first anniversary of the grant date, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":18.6,"expiration_date":"2031-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-21-013342","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919121013342/doc4.xml","form_type":"4"}},{"id":2839107,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-02-23T17:53:16.000Z","date":"2021-02-22","kind":"grant","acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on the first anniversary of the award date, subject to continued service with RDUS through such date."}],"balance_after":17695,"source":{"system":"sec-edgar","filing":"0001209191-21-013342","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919121013342/doc4.xml","form_type":"4"}},{"id":2897579,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-25T17:09:20.000Z","date":"2021-01-21","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest in full on the first anniversary of the grant date or upon an earlier Change of Control (as defined in the registrant's 2018 Stock Option and Incentive Plan)."}],"balance_after":20000,"derivative":{"exercise_price":22,"expiration_date":"2031-01-21","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-005120","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919121005120/doc4.xml","form_type":"4"}},{"id":2902198,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-01-21T00:01:52.000Z","date":"2021-01-15","kind":"grant","acquired":true,"shares":3141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2021."}],"balance_after":3141,"derivative":{"exercise_price":21.09,"expiration_date":"2031-01-15","underlying":"Common Stock","underlying_shares":3141},"source":{"system":"sec-edgar","filing":"0001104659-21-005942","document":"tm211948d2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465921005942/tm211948d2_4seq1.xml","form_type":"4"}},{"id":3096928,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-06-30T18:11:10.000Z","date":"2020-06-26","kind":"sale","acquired":false,"shares":4430,"price":123.61,"value":547592.3,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Trade made pursuant to a 10b5-1 plan executed on June 9, 2020."}],"balance_after":13290,"source":{"system":"sec-edgar","filing":"0001567619-20-012684","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920012684/doc1.xml","form_type":"4"}},{"id":3097495,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-30T00:09:04.000Z","date":"2020-06-25","kind":"grant","acquired":true,"shares":9200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2021 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":9200,"derivative":{"exercise_price":22.9,"expiration_date":"2030-06-25","underlying":"Common Stock","underlying_shares":9200},"source":{"system":"sec-edgar","filing":"0001104659-20-078225","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920078225/a4.xml","form_type":"4"}},{"id":3102986,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-22T20:11:47.000Z","date":"2020-06-18","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 18, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders."}],"balance_after":30000,"derivative":{"exercise_price":4.4,"expiration_date":"2030-06-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-20-017353","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924320017353/doc4.xml","form_type":"4"}},{"id":3131037,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-29T20:23:12.000Z","date":"2020-05-27","kind":"grant","acquired":true,"shares":4300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on May 27, 2020. Price not applicable."}],"balance_after":17720,"source":{"system":"sec-edgar","filing":"0001567619-20-011343","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761920011343/doc1.xml","form_type":"4"}},{"id":3241084,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-28T16:15:14.000Z","date":"2020-02-26","kind":"sale","acquired":false,"shares":1925,"price":17.95,"value":34553.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units."}],"balance_after":12195,"source":{"system":"sec-edgar","filing":"0001209191-20-013790","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919120013790/doc4.xml","form_type":"4"}},{"id":3252763,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2020-02-24T17:49:30.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on February 20, 2021, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":19.96,"expiration_date":"2030-02-20","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-20-012139","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919120012139/doc4.xml","form_type":"4"}},{"id":3252762,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-24T17:49:30.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 20, 2021, subject to continued service with RDUS through such date."}],"balance_after":14120,"source":{"system":"sec-edgar","filing":"0001209191-20-012139","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919120012139/doc4.xml","form_type":"4"}},{"id":3322774,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T21:38:08.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":11264,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2020."}],"balance_after":11264,"derivative":{"exercise_price":5.36,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":11264},"source":{"system":"sec-edgar","filing":"0001104659-20-000912","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465920000912/a4.xml","form_type":"4"}},{"id":3489400,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-14T20:12:25.000Z","date":"2019-06-13","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 13, 2020 or the day immediately prior to the company's 2020 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":2.83,"expiration_date":"2029-06-12","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-19-017019","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924319017019/doc4.xml","form_type":"4"}},{"id":3494086,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-11T20:14:15.000Z","date":"2019-06-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant or the date of the 2020 Annual Meeting of Stockholders of Mersana Therapeutics, Inc."}],"balance_after":25000,"derivative":{"exercise_price":4.31,"expiration_date":"2029-06-07","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001104659-19-034781","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465919034781/a4.xml","form_type":"4"}},{"id":3499216,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-06T22:12:20.000Z","date":"2019-06-04","kind":"grant","acquired":true,"shares":4430,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 4, 2019. Price not applicable."}],"balance_after":13420,"source":{"system":"sec-edgar","filing":"0001567619-19-012975","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000156761919012975/doc1.xml","form_type":"4"}},{"id":3552649,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-04-18T16:41:58.000Z","date":"2019-04-16","kind":"sale","acquired":false,"shares":1680,"price":22.22,"value":37329.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":8620,"source":{"system":"sec-edgar","filing":"0001209191-19-025249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119025249/doc4.xml","form_type":"4"}},{"id":3631885,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock (Right to Buy)","published_at":"2019-02-26T18:12:38.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on February 22, 2020, subject to continued service with RDUS through such date."}],"balance_after":10000,"derivative":{"exercise_price":19.18,"expiration_date":"2029-02-22","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-19-013698","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119013698/doc4.xml","form_type":"4"}},{"id":3631884,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-26T18:12:38.000Z","date":"2019-02-22","kind":"grant","acquired":true,"shares":5500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares were acquired pursuant to a restricted stock unit award under the 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of RDUS common stock. The restricted stock units vest in full on February 22, 2020, subject to continued service with RDUS through such date."}],"balance_after":10300,"source":{"system":"sec-edgar","filing":"0001209191-19-013698","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119013698/doc4.xml","form_type":"4"}},{"id":3660235,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2019-02-13T17:15:14.000Z","date":"2019-02-13","kind":"exercise","acquired":false,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of RDUS common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vested in full on February 13, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vested in full on February 13, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0001209191-19-009729","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119009729/doc4.xml","form_type":"4"}},{"id":3660234,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-13T17:15:14.000Z","date":"2019-02-13","kind":"exercise","acquired":true,"shares":4800,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of RDUS common stock."}],"balance_after":4800,"source":{"system":"sec-edgar","filing":"0001209191-19-009729","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919119009729/doc4.xml","form_type":"4"}},{"id":3703860,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-04T21:01:14.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":13619,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments on the last day of each calendar quarter of 2019."}],"balance_after":13619,"derivative":{"exercise_price":4.31,"expiration_date":"2019-01-02","underlying":"Common Stock","underlying_shares":13619},"source":{"system":"sec-edgar","filing":"0001104659-19-000777","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465919000777/a4.xml","form_type":"4"}},{"id":3882163,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-06-28T01:07:22.000Z","date":"2018-06-26","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of June 26, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders."}],"balance_after":15000,"derivative":{"exercise_price":9.09,"expiration_date":"2028-06-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-18-018522","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924318018522/doc4.xml","form_type":"4"}},{"id":3902154,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-06-08T00:09:35.000Z","date":"2018-06-05","kind":"grant","acquired":true,"shares":4300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 5, 2018. Price not applicable."}],"balance_after":8990,"source":{"system":"sec-edgar","filing":"0001140361-18-027782","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036118027782/doc1.xml","form_type":"4"}},{"id":3986358,"issuer":{"id":69982,"kind":"organization","name":"Mersana Therapeutics, Inc.","symbol":"MRSN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-03-21T21:19:19.000Z","date":"2018-03-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option becomes exercisable in equal quarterly installments over three years from the date of the grant."}],"balance_after":20000,"derivative":{"exercise_price":17.38,"expiration_date":"2021-03-19","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001104659-18-019370","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1442836/000110465918019370/a4.xml","form_type":"4"}},{"id":4054641,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-02-15T19:36:22.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":4800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of RDUS common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units shall vest in full on February 13, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units shall vest in full on February 13, 2019."}],"balance_after":4800,"derivative":{"underlying":"Common Stock","underlying_shares":4800},"source":{"system":"sec-edgar","filing":"0001209191-18-010543","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919118010543/doc4.xml","form_type":"4"}},{"id":4054640,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-15T19:36:22.000Z","date":"2018-02-13","kind":"grant","acquired":true,"shares":8800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on February 13, 2019, subject to continued service to the Issuer through such date."}],"balance_after":8800,"derivative":{"exercise_price":37.83,"expiration_date":"2028-02-12","underlying":"Common Stock","underlying_shares":8800},"source":{"system":"sec-edgar","filing":"0001209191-18-010543","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919118010543/doc4.xml","form_type":"4"}},{"id":4136265,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-12-11T20:19:54.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued from Footnote 4)All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on October 26, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.425, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, each option to purchase a share of the Issuer's common stock outstanding and unexercised immediately prior to the Effective Time, whether or not vested and which had a per-share exercise price of less than the $1.52 (each, an \"In the Money Option\") was canceled and converted into the right of the holder of such In the Money Company Stock Option to receive, for each Share underlying such In the Money Company Stock Option, (i) an amount in cash, without interest and subject to deduction for any required withholding taxes, equal to the excess, if any, of $1.52 over the applicable exercise price for such Share, plus (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued from Footnote 4)All other options (each, an \"Out of the Money Option\") that were outstanding and unexercised and whether or not vested, were canceled and converted into the right to receive one or more cash payments, if any, at each Milestone Payment Date (as defined in the CVR Agreement) equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds the exercise price payable per Share subject to such Out of the Money Option, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option.  Any Out of the Money Option with an exercise price per Share equal to or greater than $4.10 was cancelled without any consideration payable therefore."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This Out of the Money Option, which provided for vesting with respect to 25% of such options on October 26, 2016, with the remaining 75% of such options vesting in equal monthly installments over the next succeeding three year period, was cancelled in connection with the Merger in exchange for the right to receive one or more cash payments, without interest and subject to deduction for any required withholding taxes, equal to (i) the amount by which the Per Share Value Paid (as defined in the Merger Agreement) exceeds $2.425, less (ii) the amount of all payments previously paid with respect to such Out of the Money Option."}],"balance_after":0,"derivative":{"exercise_price":2.425,"expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-17-028414","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924317028414/doc4.xml","form_type":"4"}},{"id":4136264,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-12-11T20:19:54.000Z","date":"2017-12-11","kind":"disposition_to_issuer","acquired":false,"shares":12500,"price":1.52,"value":19000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to an Agreement and Plan of Merger, dated November 1, 2017 (the \"Merger Agreement\"), by and between Ocera Therapeutics, Inc., a Delaware corporation (the \"Issuer\"),  MAK LLC, a Delaware limited liability company (\"Parent\"), MEH Acquisition Co., a Delaware corporation and a direct wholly-owned subsidiary of Parent (\"Purchaser\"), and for limited purposes, Mallinckrodt plc, an Irish public limited company and the ultimate parent entity of Parent and Purchaser (\"Mallinckrodt\"), Purchaser was merged with and into Issuer on December 11, 2017, with the Issuer surviving as a wholly-owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) Pursuant to the terms of the Merger Agreement, all shares of common stock, $0.00001 par value per share (the \"Shares\"), of the Issuer outstanding immediately prior to the effective time of the Merger (the \"Effective Time\") , were canceled and converted automatically and without any required action on the part of the Reporting Person into the right to receive (i) $1.52 per Share in cash, without interest, plus (ii) one non-transferable contingent value right per Share (each, a \"CVR\"), which represents the contractual right under a contingent value rights agreement, by and among Parent, Continental Stock Transfer & Trust Company, and for limited purposes, Mallinckrodt (the \"CVR Agreement\"), entered  into on December 7, 2017  to receive one or more payments in cash currently estimated to be up to $2.58 per Share, contingent upon the achievement of certain milestones, in each case, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time of the Merger, each restricted stock unit outstanding, automatically and without any required action on the part of the Reporting Person, became fully vested and canceled in exchange for a right to receive, for each share of common stock underlying the restricted stock unit, (i) an amount in cash, equal to $1.52, without interest plus (ii) one CVR, less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-17-028414","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924317028414/doc4.xml","form_type":"4"}},{"id":4259856,"issuer":{"id":7191,"kind":"organization","name":"Seres Therapeutics, Inc."},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-07-10T20:42:26.000Z","date":"2017-07-07","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in four equal installments on each anniversary of 07/07/2017 or in full immediately prior to the occurrence of a change in control."}],"balance_after":30000,"derivative":{"exercise_price":11.14,"expiration_date":"2027-07-06","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-17-018146","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000089924317018146/doc4.xml","form_type":"4"}},{"id":4274441,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-22T20:42:26.000Z","date":"2017-06-20","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units shall vest in full on the earlier of the one year anniversary of the grant or the next annual meeting of shareholders; provided, in all cases, that the Reporting Person is, as of each such vesting date, then a director of the Issuer."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001274644-17-000061","document":"wf-form4_149816413114058.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000127464417000061/wf-form4_149816413114058.xml","form_type":"4"}},{"id":4288679,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2017-06-08T22:18:28.000Z","date":"2017-06-06","kind":"grant","acquired":true,"shares":4910,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Option grant vests in full on June 6, 2018"}],"balance_after":4910,"derivative":{"exercise_price":89.6,"exercise_date":"2018-06-06","expiration_date":"2027-06-05","underlying":"Common Stock","underlying_shares":4910},"source":{"system":"sec-edgar","filing":"0001140361-17-024500","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117024500/doc1.xml","form_type":"4"}},{"id":4288678,"issuer":{"id":2404,"kind":"organization","name":"BIOMARIN PHARMACEUTICAL INC","symbol":"BMRN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-06-08T22:18:28.000Z","date":"2017-06-06","kind":"grant","acquired":true,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Restricted stock units granted on June 6, 2017. Price not applicable."}],"balance_after":4690,"source":{"system":"sec-edgar","filing":"0001140361-17-024500","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1048477/000114036117024500/doc1.xml","form_type":"4"}},{"id":4431342,"issuer":{"id":124173,"kind":"organization","name":"Radius Health, Inc.","symbol":"RDUS"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-02-22T16:23:38.000Z","date":"2017-02-17","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on February 17, 2018, subject to continued service to the Issuer through such date."}],"balance_after":27500,"derivative":{"exercise_price":45.65,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":27500},"source":{"system":"sec-edgar","filing":"0001209191-17-013235","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1428522/000120919117013235/doc4.xml","form_type":"4"}},{"id":4572893,"issuer":{"id":171193,"kind":"organization","name":"Ocera Therapeutics, Inc.","symbol":"OCRX"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-28T13:16:41.000Z","date":"2016-10-26","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Option to purchase Common Stock granted by the Issuer pursuant to the Issuer's Fourth Amended and Restated 2011 Stock Option and Incentive Plan (the \"Plan\"), qualified under Rule 16b-3(d)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable with respect to 25% of the shares covered by the grant on October 26, 2016, subject to the Reporting Person's continued service to the Issuer through such date, with the balance to vest in equal monthly installments over the next succeeding three year period, subject to the Reporting Person's continued service to the Issuer through each such date."}],"balance_after":20000,"derivative":{"exercise_price":2.42,"expiration_date":"2026-10-25","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001274644-16-000143","document":"wf-form4_147766058811862.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1311569/000127464416000143/wf-form4_147766058811862.xml","form_type":"4"}},{"id":283995,"issuer":{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN"},"owners":[{"id":13975,"kind":"person","name":"Dere Willard H","position":1,"cik":"0001311569","reported_name":"Dere Willard H","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Sr. V.P., Global Dev & CMO"}}],"security":"NQSO (Right to Buy)","published_at":"2004-12-15T23:25:48.000Z","date":"2004-12-13","kind":"grant","acquired":true,"shares":13900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(WHD 12/04) This option becomes exercisable in four equal installments of 3,475 shares each commencing 12/13/2005."}],"balance_after":13900,"derivative":{"exercise_price":63.95,"exercise_date":"2004-12-13","expiration_date":"2011-12-13","underlying":"Common Stock","underlying_shares":13900},"source":{"system":"sec-edgar","filing":"0001181431-04-059040","document":"rrd61441.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143104059040/rrd61441.xml","form_type":"4"}}]}